X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Ascentage’s novel oral MDM2 inhibitor (alrizomadlin APG-115) continues to be well tolerated in combination with pembrolizumab and provides clinical benefit in several I-O relapse refractory tumor types, specifically various melanoma subtypes as well as MPNST.
Lead Product(s): Alrizomadlin,Pembrolizumab
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Alrizomadlin is an orally administered, selective, small-molecule inhibitor of the MDM2 protein, also has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction.
Lead Product(s): Alrizomadlin
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
Alrizomadlin (APG-115) is MDM2-p53 inhibitor has favorable antitumor activity and a manageable safety profile when used in combination with pembrolizumab for treatment of stage IIB-IV melanoma.
Lead Product(s): Alrizomadlin,Pembrolizumab
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
Results from this study showed that APG-115 has therapeutic potential in NSCLC harboring STK11 mutations, and shows the potential of a new treatment option for the subgroup of patients with drug resistance to approved PD-1 inhibitors.
Lead Product(s): Alrizomadlin
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. APG-115 is the first MDM2-p53 inhibitor entering clinical development in China, with multiple ongoing clinical studies in solid tumors and hematologic malignancies in Chinaand the US.
Lead Product(s): Alrizomadlin,Toripalimab
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Ascentage Pharma's APG-115 is a selective, small-molecule inhibitor of MDM2. is the first MDM2-p53 inhibitor entering clinical development in China and APG-1252 is novel drug that restores apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins simultaneously.
Lead Product(s): Alrizomadlin
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
APG-115 has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 PPI.
Lead Product(s): Alrizomadlin
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
This Phase Ib study in China is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of APG-115 as a single agent or in combination with azacitidine or cytarabine in patients with hematologic malignancies, including r/r AML and relapsed/progressed MDS.
Lead Product(s): Alrizomadlin,Azacitidine
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
Under the agreement, Ascentage will sponsor an open-label, multicenter, phase Ib/II study is designed to evaluate the safety and efficacy of APG-115 with KEYTRUDA® in multiple cohorts of solid tumors.
Lead Product(s): Alrizomadlin,Pembrolizumab
Therapeutic Area: Oncology Product Name: APG-115
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ascentage Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
